$2.8 B

EBS Mkt cap, 14-Jun-2018

$117.8 M

Emergent Biosolutions Revenue Q1, 2018
Emergent Biosolutions Net income (Q1, 2018)-4.9 M
Emergent Biosolutions EBIT (Q1, 2018)-9.5 M
Emergent Biosolutions Cash, 31-Mar-2018163.6 M

Emergent Biosolutions Financials

Emergent Biosolutions Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

404.5 m489.3 m488.8 m

Revenue growth, %

21%0%

R&D expense

108.3 m

General and administrative expense

143.7 m

Operating expense total

252 m

EBIT

89.2 m141.5 m105.5 m

EBIT margin, %

22%29%22%

Interest expense

8.2 m6.5 m7.6 m

Interest income

1.1 m

Income tax expense

29.9 m44.3 m36.7 m

Net Income

36.7 m62.9 m51.8 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

89.1 m53.9 m110.3 m138 m63.6 m126.1 m164.9 m111 m101.5 m142.9 m116.9 m100.8 m149.4 m117.8 m

Cost of goods sold

20.1 m

Gross profit

69 m

Gross profit Margin, %

77%

R&D expense

28.9 m30.3 m37.4 m44.2 m38.7 m40.9 m41.9 m34.2 m35.3 m27.2 m20.5 m25.8 m22.7 m29.1 m

General and administrative expense

22 m30.1 m30.6 m30.3 m34.5 m36.5 m31.6 m39.8 m44.1 m40.7 m35.2 m31.9 m34.5 m40.2 m

Operating expense total

50.9 m60.3 m68 m74.5 m73.2 m77.4 m73.4 m73.9 m79.5 m67.9 m55.6 m57.6 m57.2 m69.3 m

EBIT

18.1 m(25.5 m)7.9 m31 m(28.3 m)21.5 m53 m8.6 m(13.6 m)35.5 m14.9 m8.5 m47.8 m(9.5 m)

EBIT margin, %

20%(47%)7%22%(44%)17%32%8%(13%)25%13%8%32%(8%)

Interest expense

3.5 m1.7 m1.8 m1.7 m1.6 m1.6 m1.5 m1.5 m2 m1.9 m1.8 m2 m234 k

Interest income

88 k40 k31 k59 k82 k273 k104 k186 k220 k358 k373 k583 k637 k222 k

Pre tax profit

18.3 m7.5 m29.7 m19.6 m52.1 m7.3 m(14.9 m)(9.4 m)

Income tax expense

4.8 m2.5 m7.9 m(8.3 m)5.5 m15.1 m3.3 m(3.9 m)13.2 m3.2 m2.1 m12.8 m(4.5 m)

Net Income

13.5 m(20.2 m)5 m21.8 m(21.5 m)14.1 m36.9 m4 m(10.9 m)21.3 m10.5 m4.6 m33.6 m(4.9 m)

Emergent Biosolutions Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

280.5 m312.8 m271.5 m

Accounts Receivable

58.8 m120.8 m138.5 m

Inventories

65.7 m76.9 m74 m

Current Assets

432.2 m538.6 m510.2 m

PP&E

314 m331.9 m376.4 m

Total Assets

938.7 m1 b970.1 m

Accounts Payable

40.9 m46 m34.6 m

Current Liabilities

92.9 m99.6 m105.9 m

Total Liabilities

373.9 m

Additional Paid-in Capital

274.2 m318 m352.4 m

Retained Earnings

288.3 m351.1 m254.5 m

Total Equity

553.2 m660 m596.2 m

Financial Leverage

1.7 x1.6 x1.6 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

214.8 m308.7 m341 m333.4 m298.9 m270.2 m315.6 m341 m163.6 m

Accounts Receivable

99.7 m57 m69.6 m66.7 m69.6 m128.1 m102.5 m129.4 m122.1 m

Inventories

84.7 m80.1 m88.2 m96.7 m81.2 m70.7 m70.5 m68.9 m155.2 m

Current Assets

435.5 m473.5 m528.2 m528 m480 m489.2 m509.7 m556 m476.6 m

PP&E

320.1 m327.6 m342.1 m359 m362.5 m381.1 m380.2 m386.5 m411.3 m

Goodwill

52.6 m52.6 m54.9 m54.9 m41 m41 m41 m41 m49.1 m

Total Assets

943.3 m976.5 m1 b1.1 b932 m951.6 m970.5 m1 b1.1 b

Accounts Payable

41.8 m41.2 m45.6 m59 m46.3 m27.2 m29.6 m30.1 m46.2 m

Short-term debt

Current Liabilities

87 m88.7 m90.5 m103.9 m110.3 m67.7 m72.9 m75.4 m86.9 m

Long-term debt

Total Debt

Total Liabilities

381.1 m371.2 m368.9 m383.8 m384.4 m341.2 m349.9 m360.5 m187.2 m

Additional Paid-in Capital

291.3 m298 m322.4 m337.9 m342.9 m355.7 m361 m370.9 m624.5 m

Retained Earnings

280.9 m317.8 m355.1 m344.2 m214.7 m265 m269.6 m303.1 m299.6 m

Total Equity

562.3 m605.3 m667 m672.7 m547.6 m610.4 m620.6 m663.7 m881.3 m

Financial Leverage

1.7 x1.6 x1.6 x1.6 x1.7 x1.6 x1.6 x1.5 x1.2 x

Emergent Biosolutions Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

36.7 m62.9 m51.8 m

Accounts Receivable

21.4 m(64 m)(22.4 m)

Inventories

4.2 m(11.3 m)(9 m)

Accounts Payable

(9.3 m)4.7 m(14.8 m)

Cash From Operating Activities

112.3 m44.5 m53.5 m

Purchases of PP&E

(30.7 m)(44.8 m)(76.3 m)

Cash From Investing Activities

(210.1 m)(45.5 m)(76.3 m)

Cash From Financing Activities

198.9 m33.4 m(18.6 m)

Interest Paid

8.2 m

Income Taxes Paid

(4.7 m)(3.6 m)(4.6 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

15 m(20.2 m)(15.2 m)6.6 m(21.5 m)(7.4 m)29.5 m4 m(7 m)14.4 m10.5 m15.1 m48.7 m

Depreciation and Amortization

13.5 m6.8 m15.3 m24.3 m8.5 m17.3 m25.9 m8.8 m17.8 m28.2 m10.2 m20.1 m29.9 m12.4 m

Accounts Receivable

66 m17.6 m2.3 m36.1 m(5.2 m)(40.9 m)1.7 m51.2 m53.9 m45 m10.6 m36.2 m9.4 m21.8 m

Inventories

(1.2 m)(4 m)1.2 m4.7 m(16.5 m)(19 m)(14.4 m)(11.3 m)(19.7 m)(16.2 m)3.3 m3.5 m5.1 m(12.4 m)

Accounts Payable

(1.6 m)(10.7 m)(10.4 m)(11.2 m)1.1 m2.1 m1.9 m385 k11.3 m(1.3 m)81 k4.2 m3 m3.6 m

Cash From Operating Activities

88.3 m(29.2 m)(18.4 m)60.5 m(65.9 m)(63.4 m)41.4 m37.8 m35.7 m62.7 m41.7 m95.7 m129.2 m(991 k)

Purchases of PP&E

(34.4 m)(4.6 m)(9.4 m)(14.6 m)(9.1 m)(19.7 m)(33.6 m)(18.2 m)(39.2 m)(56.2 m)(20.3 m)(29.6 m)(11.6 m)

Cash From Investing Activities

(58.5 m)(182.8 m)(187.6 m)(192.8 m)(9.1 m)(19.7 m)(33.6 m)(18.2 m)(39.2 m)(56.2 m)(20.3 m)(29.6 m)(42.4 m)(11.6 m)

Cash From Financing Activities

1.1 m192.9 m194.8 m195.2 m11 m17.4 m20.5 m8.6 m24 m(20.4 m)(22.7 m)(21.9 m)(17.3 m)(2.1 m)

Income Taxes Paid

(6.9 m)(3.8 m)(5.2 m)(4.4 m)(12.2 m)630 k15.9 m3 m547 k4.8 m(5.5 m)(4.5 m)

Emergent Biosolutions Ratios

USDY, 2018

Revenue/Employee

107.3 k

Financial Leverage

1.2 x
Report incorrect company information